RxDoctor Payments Data

Scott Kasner, MD

Vascular Neurology · Philadelphia, PANPI 1285666412

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $174,002 of the $209,602 with a category attached, or 83.0%. 22 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 35.0% of the total. Reporting peaked in 2020 at $72,876 and has fallen 53.8% since, to $33,676 in 2025. Among vascular neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$209,602in general payments, 2019–2025

Across 192 payments — averaging $1091.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$73K
  • AstraZeneca$37K
  • Medtronic$19K
  • Bayer$14K
  • Shionogi Inc$13K
  • AbbVie$10K
  • plus $44K from 16 others
$723,842in research payments, 2019–2025

Across 165 payments — averaging $4386.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alnylam Pharmaceuticals Inc.$374K
  • Medtronic$174K
  • Genentech, Inc.$103K
  • Sunovion Pharmaceuticals Inc.$54K
  • Artivion, Inc.$14K
  • Takeda Pharmaceuticals U.S.A., Inc.$3K
  • plus $3K from 4 others

What the payments were for

  • Consulting fees$174,00283%
  • Speaking & faculty fees$12,5506%
  • Grants$2,5001%
  • Travel & lodging$16,5898%
  • Food & beverage$3,9612%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$209,602 in reported general payments places this provider in the 95th percentile of 52 vascular neurology providers in Pennsylvania.

See all vascular neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,574
Medicare patients
115
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban24$28,973
XareltoRivaroxaban12$8,600
Atorvastatin Calcium13$310
Donepezil Hcl24$269
ClopidogrelClopidogrel Bisulfate13$161
Amlodipine Besylate12$78

Paid to pharmacies, not to this prescriber.

Other vascular neurology in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →